UBS AM
MRSN

UBS AM’s Mersana Therapeutics MRSN Stock Holding History

UBS AM’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,103
Closed -$130K – 2581
2023
Q3 		$130K Hold
4,103
– – ﹤0.01% 2549
2023
Q2 		$422K Hold
4,103
– – ﹤0.01% 2376
2023
Q1 		$422K Hold
4,103
– – ﹤0.01% 2376
2022
Q4 		$601K Buy
4,103
+568
+16% +$96K ﹤0.01% 2101
2022
Q3 		$597K Hold
3,535
– – ﹤0.01% 2263
2022
Q2 		$408K Hold
3,535
– – ﹤0.01% 2374
2022
Q1 		$353K Buy
3,535
+1,798
+104% +$210K ﹤0.01% 2553
2021
Q4 		$270K Hold
1,737
– – ﹤0.01% 2702
2021
Q3 		$409K Hold
1,737
– – ﹤0.01% 2557
2021
Q2 		$590K Buy
1,737
+154
+10% +$58.3K ﹤0.01% 2470
2021
Q1 		$640K Sell
1,583
-1,144
-42% -$555K ﹤0.01% 2298
2020
Q4 		$1.81M Buy
2,727
+209
+8% +$116K ﹤0.01% 1723
2020
Q3 		$1.17M Buy
2,518
+433
+21% +$219K ﹤0.01% 1776
2020
Q2 		$1.22M Buy
+2,085
New +$712K ﹤0.01% 1718

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return